A phase IV clinical trial of gastrointestinal motility in adult patients with migraine before and after initiation of a calcitonin gene‐related peptide ligand (galcanezumab) or receptor (erenumab) antagonist
Headache The Journal of Head and Face Pain2022Vol. 62(9), pp. 1164–1176
Citations Over TimeTop 16% of 2022 papers
David Kudrow, Linda Anh B. Nguyen, Jack Semler, Chad Stroud, Karen Samaan, Deirdre B. Hoban, Linda Wietecha, Hai‐An Hsu, Eric Pearlman
Abstract
While the primary endpoint of this study was not met, secondary and tertiary endpoints support a within- and between-treatment change in GI effects suggesting possible mechanistic differences between ligand (GMB) and receptor (ERE) antagonism.
Related Papers
- → Responsiveness of Non-IHS Migraine and Tension-Type Headache to Sumatriptan(1997)69 cited
- → Sumatriptan in Acute Migraine: Pharmacology and Review of World Experience(1990)41 cited
- Recent advances in migraine management(1999)
- [Treatment of migraine attacks with sumatriptan].(1993)
- [The efficacy of subcutaneous sumatriptan for the treatment of migraine attack].(1999)